MIT Ambulatory Care Centers approved as only authorized local infusion center for recently released Multiple Sclerosis drug Tysabri ®

(SAVANNAH) – MIT Ambulatory Care Center of Savannah has been approved as the only authorized infusion center for the administration of Tysabri ® in the Savannah area. MIT Ambulatory Care offices of Vidalia, Brunswick and Augusta have also been authorized for Tysabri ® administration. Tysabri ® is a prescription drug approved for patients with relapsing forms of Multiple Sclerosis. Tysabri ® delays and reduces the frequencies of Multiple Sclerosis episodes. Multiple Sclerosis symptoms include blurred vision and eye pain as well as muscle weakness and numbness.

Patients interested in Tysabri ® should contact their physician, who can start the enrollment process. MIT Ambulatory Care Center staff has undergone training for Tysabri ® administration, said Donna Amyx, R.N., clinical director of MIT Ambulatory Care Center. The company is part of MIT Holdings, Inc., a Savannah healthcare company known throughout the Southeast for providing injectable medicines and treatments, home medical equipment and other healthcare services.

Established in 1990, Medical Infusion Technologies Inc. grew quickly through service contracts with local hospitals that established a history of excellence in the field of infusion. With the addition of home medical equipment to its line of expertise, the company, now MIT Holdings, Inc., became nationally known. MIT Holdings, Inc.’s mission is to provide health care at the only level acceptable to the patient … perfection.

For more information, call Donna Amyx, R.N., at (912) 691-0333. Multiple Sclerosis patients should contact their doctors for more information.
www.mitholdingsinc.com.